ALK and lung cancer: Along with the clinical observation that an ALK+ lung cancer patient responded dramatically to IGF-1R inhibition, this led the authors to propose the trial of dual inhibition of ALK and IGF-1R in ALK+ lung cancer patients; justified as a strategy to delay or overcome the development of crizotinib resistance.